Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma

Clinical Cancer Research

Volumn 18, Issue 23, 2012, Pages 6446-6459

  Hunn, Martin K ^a   Farrand, Kathryn J ^a   Broadley, Kate W R ^a   Weinkove, Robert ^a   Ferguson, Peter ^a   Miller, Rose J ^a   Field, Cameron S ^a   Petersen, Troels ^a   McConnell, Melanie J ^a   Hermans, Ian F ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BASILIXIMAB; CD1 ANTIGEN; CD4 ANTIGEN; DOXORUBICIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CELL STIMULATION; CLONAL ANERGY; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LONG TERM SURVIVAL; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR CELL; VOLUNTEER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; LUNG; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 84870380385     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0704     Document Type: Article

References (60)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010;2010:1-18.
3. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-6.
4. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 1997;278:1626-9. (Pubitemid 27516282)
5. + cells: new clues to their origin, specificity, and function. J Exp Med 1995;182:633-8.
6. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003;171:5140-7.
7. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9:28-38.
8. Fujii S-i, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003;198:267-79. (Pubitemid 36987852)
9. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 2004;114:1800-11. (Pubitemid 40385536)
10. + cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection. J Immunol 2006;177:6747-57.
11. Chung Y, Qin H, Kang C-Y, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007;110:2013-9. (Pubitemid 47443916)
12. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S-i. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007;204:2641-53. (Pubitemid 350063944)
13. Petersen TR, Sika-Paotonu D, Knight DA, Dickgreber N, Farrand KJ, Ronchese F, et al. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunol Cell Biol 2010;88:596-604.
14. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-9. (Pubitemid 35424759)
15. + NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 2004;91:1880-6.
16. + T cell development and early IL-4 production in CD1-deficient mice. Immunity 1997;6:459-67.
17. Köntgen F, Süss G, Stewart C, Steinmetz M, Bluethmann H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 1993;5:957-64. (Pubitemid 23241767)
18. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 1992;71:1205-14. (Pubitemid 23016554)
19. Kissenpfennig A, Aït-Yahia S, Clair-Moninot V, Stössel H, Badell E, Bordat Y, et al. Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol Cell Biol 2005;25:88-99. (Pubitemid 40039802)
20. Lee A, Farrand KJ, Dickgreber N, Hayman CM, Jürs S, Hermans IF, et al. Novel synthesis of α-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr Res 2006;341:2785-98. (Pubitemid 44692660)
21. Reeves JP, Reeves PA, Chin LT. Survival surgery: removal of the spleen or thymus. Curr Protoc Immunol 2001;Unit 1.10:1-11.
22. Volovitz I, Marmor Y, Azulay M, Machlenkin A, Goldberger O, Mor F, et al. Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells. J Immunol 2011; 187:5452-62.
23. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010;140:798-804.
24. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang C-R, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005;115:2572-83. (Pubitemid 41266220)
25. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701. (Pubitemid 41815875)
26. Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) 2011;34:97-106.
27. + NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 1999;163:93-101.
28. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999;189:1121-8.
29. + dendritic cells are critical for crosspriming and IL-12 production in response to systemic antigens. J Immunol 2009;183:7732-42.
30. + dendritic cells localized in the marginal zone is responsible for tolerance to cell-associated antigens. J Immunol 2009;182:4127-36.
31. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
32. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006;12(14 Pt 1):4294-305.
33. Grauer OM, Sutmuller RPM, Van Maren W, Jacobs JFM, Bennink E, Toonen LWJ, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 2008;122: 1794-802. (Pubitemid 351413426)
34. Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro-Oncology 2009;11:529-42.
35. Peralbo E, Alonso C, Solana R. Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing. Exp Gerontol 2007;42:703-8. (Pubitemid 47058868)
36. Brooks WH, Roszman TL, Mahaley MS, Woosley RE. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin Exp Immunol 1977;29:61-6. (Pubitemid 8148765)
37. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529-34. (Pubitemid 26077987)
38. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 2002;100:1728-33. (Pubitemid 34925151)
39. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000;12:987-94. (Pubitemid 30601366)
40. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647-50. (Pubitemid 29501223)
41. van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SMM. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med 2011;17:65-77.
42. Schneiders FL, Scheper RJ, Blomberg BMEv, Woltman AM, Janssen HLA, Eertwegh AJMvd, et al. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011;140:130-41.
43. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002;195:617-24. (Pubitemid 34461506)
44. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S-i. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 2007;178:2853-61. (Pubitemid 46333163)
45. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002;195:1289-302.
46. Jakubzick C, Helft J, Kaplan TJ, Randolph GJ. Optimization of methods to study pulmonary dendritic cell migration reveals distinct capacities of DC subsets to acquire soluble versus particulate antigen. J Immunol Methods 2008;337:121-31.
47. + T cells. J Immunol 2007;178:6861-6.
48. + macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010;11:303-12.
49. Asano K, Nabeyama A, Miyake Y, Qiu C-H, Kurita A, Tomura M, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011; 34:85-95.
50. + regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007;121:95-105.
51. + regulatory T cells? Eur J Immunol 2005;35:1193-200.
52. Albesiano E, Han JE, Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 2010;21:17-29.
53. Melief CJM. Cancer immunotherapy by dendritic cells. Immunity 2008;29:372-83.
54. Fernandes RS, Kirszberg C, Rumjanek VM, Monteiro RQ. On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J Thromb Haemost 2006;4:1546-52.
55. Bastida E, Ordinas A, Escolar G, Jamieson GA. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 1984;64:177-84. (Pubitemid 14083873)
56. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50. (Pubitemid 32910851)
57. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 2004;109:893-9. (Pubitemid 38500746)
58. Villeneuve J, Galarneau H, Beaudet M-J, Tremblay P, Chernomoretz A, Vallières L. Reduced glioma growth following dexamethasone or antiangiopoietin 2 treatment. Brain Pathol 2008;18:401-14. (Pubitemid 351782849)
59. Johansson U, Macey MG, Kenny D, Provan D, Newland AC. α-Galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment. Br J Haematol 2004;125:400-4. (Pubitemid 38621773)
60. + dendritic cells. Proc Natl Acad Sci USA 1996;93:2588-92.